Skip to main content

Table 1 Clinical trial development by MiRNA; data were adapted from https://clinicaltrials.gov

From: MicroRNAs signatures, bioinformatics analysis of miRNAs, miRNA mimics and antagonists, and miRNA therapeutics in osteosarcoma

Study title

Conditions

Interventions

Study type and phase

Plasma microRNA, lung cancer

Lung cancer

Screening

Interventional study, not applicable

MicroRNA-155 and telomerase reverse transcriptase, non-muscle invasive bladder cancer

bladder cancer and disease

Diagnostic method: miRNA -155

Diagnostic method: Human telomerase reverse transcriptase

interventional, not applicable

Plasma microRNAs, pelvic gynecologic tumors

Ovarian cancer

Endometrial cancer

Other: blood sample

Interventional study, not applicable

Circulating miRNAs, breast cancer

Breast cancer

Drug: tamoxifen, letrozole, anastrozole, exemestane

Interventional study, Phase 4

A 6 microRNA Tool for Stratifying Stage II colon cancer

Colonic

Chemotherapy

A 6 microRNA stratified tool

Interventional study, Not applicable

MicroRNA in NAF, serum, and tissue, breast cancer

Breast Cancer

Ductal carcinoma in situ

Drug application: intranasal oxytocin

Interventional study, Phase 2

A multicenter phase I study of MRX34, MicroRNA miR-RX34 liposomal injection

Primary liver cancer

SCLC

Lymphoma

Drug application: MRX34

Interventional study, Phase 1

MicroRNA involved in cutaneous squamous cell carcinoma

Cancer of the Skin

Genetic: arm A

Interventional study, not applicable

Plasma miRNAs for Predicting Radiosensitivity in Advanced Non-small Cell Lung Cancer

Advanced non-small cell lung cancer

Radiotherapy

Interventional study, not applicable